echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAHA: The effect of medical disprogency on malignant arrhyth arrhythmic in prostate cancer patients

    JAHA: The effect of medical disprogency on malignant arrhyth arrhythmic in prostate cancer patients

    • Last Update: 2021-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical hypernomic, gonogen-promoting hormone-releasing hormone astrogens and anti-androgens have been widely used in the treatment of prostate cancer.
    steroid sex hormones affect the function of the heart's ion channels.
    , however, few studies have assessed the effects of medical de-trending on arrhyth arrhythmics.
    recently, a study published in JAHA, an authoritative journal in the field of cardiovascular disease, included 149 prostate cancer patients who treated prostate cancer with progesterone-releasing hormones combined/not combined with anti-androgens.
    researchers recorded changes in the electrical map of the center of the subject's treatment process and its relationship to malignant arrhyth arrhythmics.
    QT inter-period (394±32 to 406±39 ms (P<0.001)) compared to baseline QT inter-period and corrected QT inter-period (QTc, 416±27 to 439±31 ms (P<0.001) has been extended.
    119 patients (79.9%) had longer QTc intervals than the baseline during treatment.
    in 2 patients (1.3%) who did not have structural heart disease, the ontology was reversed (TdP) and cerio-fibrillation (VF) for more than 6 months after starting treatment.
    QTc intervals in patients with TdP/VF increased by more than 80 ms compared to pre-treatment.
    , however, in patients without TdP/VF, the prevalence of QTc intervals increased by more than 50ms compared to pre-treatment by 11%, while in only 4 patients (3%) QTc intervals increased by more than 80ms compared to pre-treatment intervals.
    thus, medical de-trending prolongs QT/QTc intervals in most prostate cancer patients, which can lead to TdP/VFs even in patients who do not have an extended risk of QT interstitiosis before treatment.
    QTc interval of more than 50 ms than before treatment may be a predictive factor for the occurrence of TdP/VF.
    to prevent the occurrence of malignant arrhyth arrhythmic, the monitoring of QTc interval should be paid attention to in the whole process of medical dissocation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.